ArticleNeuropsychopharmacology : official publication of the American College of Neuropsychopharmacology2012
The effect of dopamine agonists on adaptive and aberrant salience in Parkinson's disease.
Article in Neuropsychopharmacology : official publication of the American College of Neuropsychopharmacology, 2012. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 21 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
21 citing papers in PubMed, 45 citations in OpenAlex.
- A single dose of L-DOPA changes perceptual experiences and decreases latent inhibition in Parkinson's disease.Journal of neural transmission (Vienna, Austria : 1996) · 2017Trial
- Refining mechanistic models of hallucinations for enhanced translatability.Translational psychiatry · 2025Review
- Aberrant salience in acute versus chronic schizophrenia: Do medication and positive symptoms make a difference?Indian journal of psychiatry · 2024Article
- The Lack of Dopamine Transporter Is Associated With Conditional Associative Learning Impairments and Striatal Proteomic Changes.Frontiers in psychiatry · 2022Article
- Incentive motivation: 'wanting' roles of central amygdala circuitry.Behavioural brain research · 2021Review
- Components determining the slowness of information processing in parkinson's disease.Brain and behavior · 2021Article
- Schizotypy in Parkinson's disease predicts dopamine-associated psychosis.Scientific reports · 2021Article
- Altered subcortical emotional salience processing differentiates Parkinson's patients with and without psychotic symptoms.NeuroImage. Clinical · 2020Article
- Chronic psychosocial stressors are associated with alterations in salience processing and corticostriatal connectivity.Schizophrenia research · 2019Article
- Dopaminergic drug treatment remediates exaggerated cingulate prediction error responses in obsessive-compulsive disorder.Psychopharmacology · 2019Article
- Management of Psychosis in Parkinson's Disease: Emphasizing Clinical Subtypes and Pathophysiological Mechanisms of the Condition.Parkinson's disease · 2017Review
- An Integrative Perspective on the Role of Dopamine in Schizophrenia.Biological psychiatry · 2017Review
- Validating the construct of aberrant salience in schizophrenia - Behavioral evidence for an automatic process.Schizophrenia research. Cognition · 2016Article
- Striatal dopamine, reward, and decision making in schizophrenia.Dialogues in clinical neuroscience · 2016Review
- Aberrant Salience Is Related to Reduced Reinforcement Learning Signals and Elevated Dopamine Synthesis Capacity in Healthy Adults.The Journal of neuroscience : the official journal of the Society for Neuroscience · 2015Article
- Dopamine, reward learning, and active inference.Frontiers in computational neuroscience · 2015Article
- A pilot psychometric study of aberrant salience state in patients with Parkinson's disease and its association with dopamine replacement therapy.Neurological sciences : official journal of the Italian Neurological Society and of the Italian Society of Clinical Neurophysiology · 2014Article
- The effects of methylphenidate on cerebral activations to salient stimuli in healthy adults.Experimental and clinical psychopharmacology · 2014Article
- In a rush to decide: deep brain stimulation and dopamine agonist therapy in Parkinson's disease.Journal of Parkinson's disease · 2014Article
- Pain and analgesia: the value of salience circuits.Progress in neurobiology · 2013Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors at 4 institutions in 2 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Clinical evidence suggests that after initiation of dopaminergic medications some patients with Parkinson's disease (PD) develop psychotic symptoms, such as hallucinations and delusions. Here, we tested the hypothesis that the neurocognitive basis of this phenomenon can be defined as the formation of arbitrary and illusory associations between conditioned stimuli and reward signals, called aberrant salience. Young, never-medicated PD patients and matched controls were assessed on a speeded reaction time task in which the probe stimulus was preceded by conditioned stimuli that could signal monetary reward by color or shape. The patients and controls were re-evaluated after 12 weeks during which the patients received a dopamine agonist (pramipexole or ropinirole). Results indicated that dopamine agonists increased both adaptive and aberrant salience in PD patients, that is, formation of real and illusory associations between conditioned stimuli and reward, respectively. This effect was present when associations were assessed by means of faster responding after conditioned stimuli signaling reward (implicit salience) and overt rating of stimulus-reward links (explicit salience). However, unusual feelings and experiences, which are subclinical manifestations of psychotic-like symptoms, were specifically related to irrelevant and illusory stimulus-reward associations (aberrant salience) in PD patients receiving dopamine agonists. The learning of relevant and real stimulus-reward associations (adaptive salience) was not related to unusual experiences. These results suggest that dopamine agonists may increase psychotic-like experiences in young patients with PD, possibly by facilitating dopaminergic transmission in the ventral striatum, which results in aberrant associations between conditioned stimuli and reward.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.